Gene therapy biotech Lexeo Therapeutics eyes $113M in Nasdaq IPO proceedsnews2023-10-30T12:54:42+00:00October 30th, 2023|Endpoints News|
Vir eyes expansion beyond infectious diseases and into oncology, neurology with new leadershipnews2023-10-30T12:05:28+00:00October 30th, 2023|Endpoints News|
Merck KGaA pays $169M upfront in deal for Hengrui’s PARP1 inhibitor and ADCnews2023-10-30T11:34:29+00:00October 30th, 2023|Endpoints News|
MapLight raises $225M in bid to make better schizophrenia drug than pathfinder Karuna news2023-10-30T11:30:52+00:00October 30th, 2023|Endpoints News|
Abingworth secures $356M to help Big Pharma expand drug labels, support PhIII trialsnews2023-10-30T08:00:33+00:00October 30th, 2023|Endpoints News|
GSK’s checkpoint inhibitor plus chemotherapy prolongs survival for endometrial cancer patients in PhIII studynews2023-10-30T06:00:55+00:00October 30th, 2023|Endpoints News|
Roche’s $7.1B bet on Roivant drug; ADCs and other #ESMO23 dispatch; Highlights from Alzheimer’s confab; Q3 pharma drama; and morenews2023-10-28T10:00:11+00:00October 28th, 2023|Endpoints News|
Another Eylea threat: Roche expands label for blockbuster eye drug Vabysmonews2023-10-27T19:01:11+00:00October 27th, 2023|Endpoints News|
European regulator says evidence shows no thyroid cancer link to GLP-1s such as Novo Nordisk’s Ozempicnews2023-10-27T18:49:56+00:00October 27th, 2023|Endpoints News|
EMA chief tells European Parliament it’s no longer in crisis mode on pandemic, ready to handle shortagesnews2023-10-27T18:23:12+00:00October 27th, 2023|Endpoints News|
